Cargando…
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies
Autores principales: | Iwanami, Akio, Cloughesy, Timothy F., Cavenee, Webster K., Mischel, Paul S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680520/ https://www.ncbi.nlm.nih.gov/pubmed/23624839 http://dx.doi.org/10.4161/cc.24747 |
Ejemplares similares
-
mTORC2 dictates Warburg effect and drug resistance
por: Masui, Kenta, et al.
Publicado: (2014) -
mTOR, AMBRA1, and autophagy: An intricate relationship
por: Nazio, Francesca, et al.
Publicado: (2013) -
mTOR/PRAS40 interaction: Hypertrophy or proliferation
por: Völkers, Mirko, et al.
Publicado: (2013) -
mTOR signaling in glioblastoma: lessons learned from bench to bedside
por: Akhavan, David, et al.
Publicado: (2010) -
Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance
por: Wu, Si-Han, et al.
Publicado: (2014)